Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Similar” Biologics Could Use One Clinical Trial For All Indications – Teva

Executive Summary

Abbreviated applications for "similar" follow-on biologics could include clinical data in one indication to support approval in all innovator indications, Teva Senior Director Global Clinical Research Yafit Stark, PhD, said
Advertisement

Related Content

Follow-On Proteins May Present Problem For Post-Marketing Surveillance
Follow-On Proteins May Present Problem For Post-Marketing Surveillance
BIO “Follow-On” Biologics Risk-Based Proposal Would Require Clinical Tests
BIO “Follow-On” Biologics Risk-Based Proposal Would Require Clinical Tests
GPhA Offers Risk-Based Approach To “Follow-On” Biologics Immunogenicity
GPhA Offers Risk-Based Approach To “Follow-On” Biologics Immunogenicity
Follow-On Biologics Studies Depend On “Switchability”, MDS Pharma Says
Follow-On Biologics Studies Depend On “Switchability”, MDS Pharma Says
Follow-On And Wait: FDA Defers Action On Sandoz’s Human Growth Hormone
Follow-On And Wait: FDA Defers Action On Sandoz’s Human Growth Hormone

Topics

Advertisement
UsernamePublicRestriction

Register

PS044698

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel